Effectiveness of 2-dose Vaccination with MRNA COVID-19 Vaccines Against COVID-19–associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

Details

• Personal Author:
  Embi, Peter J. ; Levy, Matthew E. ; Naleway, Allison L. ; Patel, Palak ; Gaglani, Manjusha ; Natarajan, Karthik ; Dascomb, Kristin ; Ong, Toan C. ; Klein, Nicola P. ; Liao, I-Chia ; Grannis, Shaun J. ; Han, Jungmi ; Stenehjem, Edward ; Dunne, Margaret M. ; Lewis, Ned ; Irving, Stephanie A. ; Rao, Suchitra ; McEvoy, Charlene ; Bozio, Catherine H. ; Murthy, Kempapura ; Dixon, Brian E. ; Grisel, Nancy ; Yang, Duck-Hye ; Goddard, Kristin ; Kharbanda, Anupam B. ; Reynolds, Sue ; Raiyani, Chandni ; Fadel, William F. ; Arndorfer, Julie ; Rowley, Elizabeth A. ; Fireman, Bruce ; Ferdinands, Jill ; Valvi, Nimish R. ; Ball, Sarah W. ; Zerbo, Ousseny ; Griggs, Eric P. ; Mitchell, Patrick K. ; Porter, Rachael M. ; Kiduko, Salome A. ; Blanton, Lenee ; Zhuang, Yan ; Steffens, Andrea ; Reese, Sarah E. ; Olson, Natalie ; Williams, Jeremiah ; Dickerson, Monica ; McMorrow, Meredith ; Schrag, Stephanie J. ; Verani, Jennifer R. ; Fry, Alicia M. ; Azziz-Baumgartner, Eduardo ; Barron, Michelle A. ; Thompson, Mark G. ; DeSilva, Malini B.
• Corporate Authors:
  Regenstrief Institute. ; Indiana University School of Medicine. ; Westat. ; Center for Health Research (Kaiser-Permanente Medical Care Program. Northwest Region) ; CDC COVID-19 Response Team. ; Texas A&M University College of Medicine. Baylor Scott & White Health. ; Columbia University. Department of Biomedical Informatics. ; New York Presbyterian Hospital. ; Intermountain Healthcare (Utah). Division of Infectious Diseases and Clinical Epidemiology. ; University of Colorado Anschutz Medical Campus. Department of Medicine. ; Kaiser Permanente Vaccine Study Center. ; Regenstrief Institute for Health Care‏. Center for Biomedical Informatics. ; HealthPartners Institute. ; Indiana University. Fairbanks School of Public Health. ; Children’s Minnesota (Minneapolis, Minnesota) ; VISION Network.
• Description:
  What is already known about this topic? Studies suggest that immunocompromised persons who receive COVID-19 vaccination might not develop high neutralizing antibody titers or be as protected against severe COVID-19 outcomes as are immunocompetent persons.
  
  What is added by this report? Effectiveness of mRNA vaccination against laboratory-confirmed COVID-19–associated hospitalization was lower (77%) among immunocompromised adults than among immunocompetent adults (90%). Vaccine effectiveness varied considerably among immunocompromised patient subgroups.
  
  What are the implications for public health practice? Immunocompromised persons benefit from COVID-19 mRNA vaccination but are less protected from severe COVID-19 outcomes than are immunocompetent persons. Immunocompromised persons receiving mRNA COVID-19 vaccines should receive 3 doses and a booster, consistent with CDC recommendations, practice nonpharmaceutical interventions, and, if infected, be monitored closely and considered early for proven therapies that can prevent severe outcomes.
  
  Suggested citation for this article: Embi PJ, Levy ME, Naleway AL, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021. MMWR Morb Mortal Wkly Rep. ePub: 2 November 2021.
  
  mm7044e3.htm?s_cid=mm7044e3_x
  
  mm7044e3-H.pdf
  
  
• Subjects:
  Adult CoronaVirus Infections/Prevention & Control COVID-19 Vaccines COVID-19/Prevention & Control Hospitalization Immunocompromised Host Vaccination
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2021; v. 70 Early Release
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Document Type:
  Journal Article
• Place as Subject:
  United States
• Pages in Document:
  7 pdf pages
• Volume:
  70
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:56722e8577609f492bbd5ea6c00bab450c9436f0a8dfed41ac920e44f9599f85e227bcd0b4f721ea154d234571d8606d193a3a46688a032286ab576fce153de8
• Download URL:
  https://stacks.cdc.gov/view/cdc/111200/cdc_111200_DS1.pdf
• File Type:
  [PDF - 494.37 KB ]